Curaleaf Urges Aurora Shareholders to Accept 45% Premium Takeover Bid

The Shareholder Letter Frames the Bid as a Clear Value Proposition

Curaleaf CEO Boris Jordan told Aurora shareholders Tuesday they can accept a 45% premium or remain invested in a company facing operational headwinds. The letter, sent directly to Aurora's shareholder base, bypasses Aurora's board and management—a hallmark move in hostile takeovers when the target company has rejected initial overtures or failed to engage constructively.

Jordan's message is blunt. Take the premium now. His letter frames the choice as binary: cash out at a significant markup or continue holding shares in a company that's struggled with profitability and market-share erosion in Canada's oversupplied cannabis market. Curaleaf hasn't disclosed the total dollar value of the offer, but the 45% premium figure suggests the bid values Aurora substantially above its recent market capitalization.

This is Curaleaf's first public direct appeal to Aurora's investor base, signaling the U.S. operator believes it can win shareholder support even without Aurora board backing. That strategy works only if institutional holders see better risk-adjusted returns in the Curaleaf offer than in Aurora's standalone plan.

Why Curaleaf Wants Aurora—and Why the Math Gets Complicated

The bull case for Curaleaf: Aurora's Canadian cultivation infrastructure and European medical footprint at a steep discount. Aurora operates large-scale production facilities in Alberta and has distribution agreements across the EU, assets Curaleaf lacks. Acquiring Aurora would give Curaleaf immediate international scale and a hedge against U.S. federal uncertainty.

The bear case? Integration risk is enormous. Aurora's cost structure has been a chronic problem—its per-gram production costs remain above the Canadian wholesale average, and its balance sheet has required multiple recapitalizations. Curaleaf would inherit operational complexity, potential write-downs, and a brand portfolio that's lost consumer traction in Canada's discount-driven recreational market.

Curaleaf's own fundamentals matter here, and they're mixed. The company reported positive adjusted EBITDA in its most recent quarter but remains unprofitable on a GAAP basis and carries roughly $500 million in debt. Taking on Aurora's liabilities—and the capital required to turn around its operations—could strain Curaleaf's liquidity and delay its path to free cash flow. Investors will weigh whether the 45% premium is generous or whether it undervalues Aurora's long-term optionality in international medical markets.

What Happens Next—Tender Deadline and Regulatory Hurdles

Curaleaf hasn't publicly disclosed a tender deadline, but hostile bids typically set a 30-60 day window for shareholders to accept. Aurora's board will almost certainly issue a formal response, likely advising shareholders to reject the offer and outlining its standalone strategic plan. Proxy advisory firms like ISS and Glass Lewis will weigh in. Their recommendations often sway institutional votes.

Regulatory approval is the other variable. Any cross-border cannabis M&A requires sign-off from Canadian securities regulators and potentially from the Committee on Foreign Investment if U.S. capital markets are involved. If Curaleaf's bid involves stock consideration, it also triggers disclosure and valuation questions under Canadian takeover rules.

For background on this evolving story, see the CannIntel topic hub on the Curaleaf-Aurora takeover bid.

Watch for Aurora's board response, expected within two weeks, and any competing bid from another strategic or financial buyer. If no white knight emerges and institutional shareholders see no credible turnaround thesis, Curaleaf's 45% premium may prove hard to refuse.